{
  "docId": "019de073-7b6a-72bb-8d98-812d56d63617",
  "docSlug": "f8b2787992eb3375620f74057447d0c9",
  "documentTitle": "Aravive | Investor Presentation Deck | 39 slides",
  "authorId": "aravive",
  "authorName": "Aravive",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 31,
  "pageCount": 39,
  "prevPage": 30,
  "nextPage": 32,
  "slideType": "traction",
  "function": "show_traction",
  "density": "balanced",
  "nDataPoints": 10,
  "notes": "Includes a footnote comparing results to a historical P3 study.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-7b6a-72bb-8d98-812d56d63617/31",
  "deckHref": "/decks/019de073-7b6a-72bb-8d98-812d56d63617",
  "deckJsonHref": "/decks/019de073-7b6a-72bb-8d98-812d56d63617.json",
  "deckAnchorHref": "/decks/019de073-7b6a-72bb-8d98-812d56d63617#slide-31",
  "components": [
    {
      "bbox": {
        "h": 0.03,
        "w": 0.2,
        "x": 0.7,
        "y": 0.92
      },
      "kind": "paragraph",
      "text": "Data cutoff August 8, 2022",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "43012c54-f84e-435f-b90f-853f57a8baa6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.8,
        "x": 0.05,
        "y": 0.85
      },
      "kind": "source-note",
      "text": "1 Confirmed Response rate in P3 study of gemcitabine + nab-paclitaxel was 23% ( N Engl J Med 369;18 October 31, 2013)",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "91c18b81-e8c8-4d2d-b977-cfb34664bec9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.9,
        "x": 0.05,
        "y": 0.175
      },
      "kind": "table",
      "text": "Best Response | All P1b Patients (N = 21) | Confirmed Partial Response | 6 (29%) | Stable Disease | 5 (24%) | Progressive Disease | 5 (24%) | Not Evaluable | 3 (14%) | Not Applicable | 2 (10%)",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8a5c0ba3-d3e8-4773-960d-439e4415ab4f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Initial Anti-Tumor Activity from Phase 1b PDAC Trial: 15 mg/kg Batiraxcept + Gemcitabine+ nab-Paclitaxel",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "63c520e1-c310-4ad2-b45b-6e7d05520486",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "4ccce115-5ca7-4d2c-b3b3-c8f94a7c6cf9",
      "evidence": "table/data: Best Response | All P1b Patients (N = 21) | Confirmed Partial Response | 6 (29%) | Stable Disease | 5 (24%) | Progressive Disease | 5 (24%) | Not Evaluable | 3 (14%) | Not Applicable | 2 (10%)",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}